About
Prolocor develops a novel diagnostic test to quantify FcγRIIa receptors on platelets to improve risk assessment and personalized treatment decisions in cardiovascular disease and cancer patients.
Explore Prolocor's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.